Relapsing Multiple Sclerosis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Relapsing Multiple Sclerosis Emerging Therapy and TPP Insights

Thelansis’s “Relapsing Multiple Sclerosis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Relapsing Multiple Sclerosis Overview

Relapsing multiple sclerosis (RMS)—encompassing both relapsing-remitting MS (RRMS) and active secondary progressive MS (aSPMS)—is a chronic, immune-mediated demyelinating and neurodegenerative disease of the central nervous system. It is clinically characterized by distinct, acute exacerbations of focal neurological dysfunction (relapses) followed by periods of partial or complete recovery, driven by autoreactive T-cell and B-cell infiltration that causes irreversible axonal transection and progressive gliosis. Diagnosis is strictly governed by the McDonald criteria, requiring clinical or MRI evidence of neuroinflammatory lesions disseminated in both time and space. Because the insidious accumulation of underlying axonal damage inevitably drives long-term, progression-independent neurologic disability, the modern therapeutic paradigm has aggressively shifted away from older, modestly effective injectable immunomodulators toward early, high-efficacy intervention. The current standard of care heavily prioritizes highly efficacious disease-modifying therapies (DMTs)—most notably B-cell-depleting anti-CD20 monoclonal antibodies (such as ocrelizumab and ofatumumab), alongside sphingosine 1-phosphate (S1P) receptor modulators and the anti-integrin natalizumab—to dramatically suppress clinical relapses, silence MRI-detectable disease activity, and maximize the preservation of long-term neurologic function.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Relapsing Multiple Sclerosis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026